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Computational predictions of corroles as a class
of Hsp90 inhibitors†
Ruijie D. Teo,‡ab Sijia S. Dong,‡ab Zeev Gross,c Harry B. Grayb and
William A. Goddard III*ab
Corroles have been shown experimentally to cause cell cycle arrest, and there is some evidence that
this might be attributed to an inhibitory eﬀect of corroles on Heat shock protein 90 (Hsp90), which is
known to play a vital role in cancer cell proliferation. In this study, we used molecular dynamics to
examine the interaction of gallium corroles with Hsp90, and found that they can bind preferentially
to the ATP-binding N-terminal site. We also found that structural variations of the corrole ring can
influence the binding energies and aﬃnities of the corrole to Hsp90. We predict that both the bis-
carboxylated corrole (4-Ga) and a proposed 3,17-bis-sulfonated corrole (7-Ga) are promising alternatives
to Ga(III) 5,10,15-tris(pentafluorophenyl)-2,17-bis(sulfonic acid)-corrole (1-Ga) as anti-cancer agents.
Introduction
Corroles, and in particular the metal chelates of 5,10,15-
tris(pentafluorophenyl)-2,17-bis(sulfonic acid)-corrole 1-H3, 1-M
(Scheme 1), have become increasingly important in recent years
due to their utility in medical applications. The iron and
manganese complexes display excellent catalytic activity for
decomposition of the main reactive oxygen species (ROS) and
reactive nitrogen species (RNS) that are implicated in numerous
diseases. Many beneficial eﬀects have been disclosed for 1-Fe in
model systems of diabetes,1 neurodegeneration,2 optic neuropathy,3
and atherosclerosis.4 1-Mn and similar manganese corroles are
most eﬀective for the attenutation of molecular and intracellular
nitration. 1-Sb is able to photodynamically inactivate mold fungi
spores.5 1-Al and 1-Ga are highly fluorescent,6 and 1-Au and 1-Ga
have been shown to exhibit cytotoxicity in a number of cancer
cell lines.7
These amphiphilic bis-sulfonated metallocorroles interact
with a variety of proteins, including albumin8 and transferrin.9
Recently, metallocorroles have been shown to bind tightly to
low-density lipoprotein (LDL) and a sub-fraction of high-density
lipoprotein (HDL) upon mixing with human serum to protect
them from oxidative/nitrative damage.10
1-Ga spontaneously assembles with a heregulin-modified
protein directed at the human epidermal growth factor receptor
(HER), leading to targeted tumor cell death in a mouse model.
This can be observed by the intense fluorescence of the corrole
rendering it suitable for both cellular and whole animal optical
imaging.11,12 Although there have been large advances in
Scheme 1 Synthesis of cytotoxic metallocorroles 1-M.
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elucidating the cancer cell-killing mechanism by 1-Ga,16,17 both
free and protein-conjugated, many open questions about its
intracellular behavior remain unanswered.
One such class of intracellular proteins that have been
implicated in cancer is heat shock proteins (Hsp).18 Hsp are
ubiquitous molecular chaperones distributed from bacteria to
animal cells and essential mediators of signal-transduction and
cell cycle progression in prokaryotes and eukaryotes.19 In
particular, Hsp90, a subclass of Hsp that is often implicated
in tumorigenesis and tumor progression, aids in a wide range of
intracellular processes – protein assembly, trafficking, folding,
degradation, and neurodegenerative diseases.20,21 Since Hsp90
has a concentration 2–10 times higher in tumors than normal
cells, it has been recognized as a potential target for cancer.22
Indeed the development of Hsp90 inhibitors has been rapid – 17
agents had entered clinical trials in 2012.23 Potent Hsp90
inhibitors such as geldanamycin and radicicol (Fig. 1) block
the ATP binding/hydrolysis site at the N-terminal nucleotide-
binding pocket, inhibiting its function, depleting oncogenic
clients, and engendering antitumor activity.23–25 Studies in
both human breast cancer cells and dopaminergic neural cells
showed that 19-substituted benzoquinone ansamycin (BQA)
macrocycles are effective Hsp90 inhibitors while possessing
markedly reduced toxicity to normal endothelial and epithelial
cells than their parent quinones.26
Previous work showed that tubocapsenolide A inhibits activity
of the Hsp90–Hsp70 chaperone complex, leading to destabiliza-
tion of Hsp90 client proteins and subsequent cell cycle arrest
and apoptosis in MDA-MB-231 cells.27 In 2012, Termini and
coworkers found that 1-Ga causes mitotic cell cycle arrest in the
same MDA-MB-231 cell line.28 Most recently, protoporphyrin IX
(PPIX) treatment was purported to inhibit the chaperone activity
of Hsp90, accelerating protein degradation of HIF-1a.29 These
developments, coupled with the structural similarity of PPIX and
1-Ga, led us to hypothesize that 1-Ga’s tumor killing ability is
from its inhibition of Hsp90. In this study, we predicted the
binding site for 1-Ga and its derivatives (Fig. 2) to Hsp90 which
we compared with the predicted binding sites of PPIX and
ATP with Hsp90. Then we carried out molecular dynamics
(MD) simulation of the docked complexes. These studies led
to corrole–Hsp90 interactions that support our hypothesis
suggesting how corroles might inhibit Hsp90. These findings
also provide insight into designing potent corrole-based anti-
cancer drugs.
Procedures
Preparation of the protein and ligands
1- to 5-Ga were constructed using the crystal structure of a
structurally similar gold corrole.30 Starting with the co-crystal
structure of Hsp90 with geldanamycin (protein data bank (PDB)
code: 1YET) we removed the ligand and all crystallographic
water molecules. The structure for PPIX was obtained from a
co-crystal structure of human ferrochelatase with PPIX (PDB
code: 2HRE) while the structure of ATP was obtained from the
crystal structure of ATP-boundmonomeric actin (PDB code: 2HF4).
All ligands tested were then geometrically optimized with quantum
mechanics [the B3LYP-D3 level of density functional theory (DFT)
that includes D3 corrections for van der Waals attraction] using the
6-31G**++ basis set for the non-metal atoms and the LACV3P31,32
basis set for the metal and including the Poisson–Boltzmann
model for implicit solvation by water, as implemented in the
Jaguar 8.0 package.33 We obtained the Mulliken charges from
these DFT calculations for use in docking the ligands to the
protein structure of Hsp90.
Molecular docking
Molecular docking studies were performed using our GenDock34,35
procedure using the DREIDING force field (FF).36 GenDock has
been shown to be able to predict protein–ligand binding sites
and energy consistent with experimental findings for a number
of cases including G protein-coupled receptors34,37 and cyclin-
dependent kinase 5.38 We first generated all possible ligand-
binding positions in the alanized protein (the protein with all
hydrophobic residues mutated to alanine) by filling the binding
regions with spheres that are classified into boxes with 10 Å sides.
Then we used PyMOL39 to choose spheres in the N-terminal
binding pocket of Hsp9040 for docking. For each ligand, we
screened 5 million poses without energy evaluation and kept
the 98–109 poses that could fit into the chosen binding pocket.
The poses were clustered into 3 families by RMSD and all poses
were maintained. We then de-alanized these selected poses
using SCREAM. Then we neutralized all charged residues in theFig. 1 Structures of geldanamycin 1 and radicicol 2.
Fig. 2 Compounds investigated in this study – gallium corrole analogues
1-Ga to 5-Ga, and PPIX (with the exception of ATP).
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protein except for Lys58 and Lys112 before geometry optimiza-
tion of the poses, as both Lys58 and Lys112 are important
mediators in ligand–Hsp90 interactions.41
Molecular dynamics
Starting with the docked structures, we inserted the ligand–
protein into an equilibrated water box and carried out molecular
dynamics (MD) calculations to relax the ligand–protein complex
while allowing water to diffuse throughout the complex. These
calculations used Amber force field with the NAMD 2.942 MD
software. We carried out 10 ns of MD at 310 K to select the best
1-Ga–Hsp90 complex from the docking studies. Our procedure
was to use VMD43 to build an equilibrated orthorhombic water
box that included the ligand–protein complex at the center and
extended 10 Å beyond the protein in all 6 directions. Then we
eliminated all water molecules within 5 Å of the complex. Using
tleap from AmberTools11,44 we added sufficient Cl and Na+
ions to neutralize the complex and to give a physiological salt
concentration of 0.9% w/v. The final system has 29996 atoms.
Then we minimized the solvent for 5000 steps with the protein
and ligand fixed, followed by 1 ns of NPT dynamics of the solvent
using a bath temperature of 310 K and a pressure of 1 atm. We
then conjugate gradient minimized the whole resulting system
for 5000 steps, followed by 10 ns NPT dynamics for the whole
system at 310 K and 1 atm. We used the Nose´–Hoover Langevin
piston pressure control, with a damping coefficient of 5 ps1.
The particle mesh Ewald (PME) method was applied for electro-
static interactions. Finally, the analysis of MD trajectories were
performed using VMD.
Corrole Amber parameters for MD
Since Amber does not have a force field for corroles, we
introduced new atom types and approximated the force con-
stants from a published set of cobalt corrole parameters45 as
well as GAFF.46 The well depth for Ga nonbonding interaction
was taken from UFF.47 For the equilibrium bond distances and
angles, we used the average bond distances and angles from the
structure optimized using DFT (B3LYP-D3/LACV3P for Ga and
B3LYP-D3/6-31G**++ for all other atoms). These modified force
field parameters are in Tables S1–S6 of the ESI.†
Results and discussion
Of all the gallium corroles studied (Table 1), we find that 1-Ga
has the strongest bonding to Hsp90 [based on the unified-cavity
energy (ucav) and the snap binding energy (snapbe)]. 1-Ga also
has the largest number of interactions of favourable interactions
as indicated in Table 1. We find that the sulfonate groups of 1-Ga
both make salt-bridges with the positively-charged amino group
of Lys112, while Lys58 ‘hangs’ from the top to form a cation–pi
interaction with the conjugated corrole p-system (Fig. 3a). Most
interesting is that we find an uncommon anion–p interaction
between the negatively-charged carboxylate group of Asp102
and the electron-poor –C6F5 group. We also find interactions
for the docking of other gallium corrole analogues, including
2-Ga, 3-Ga, and 5-Ga (Fig. 3). We predict that 4-Ga is bonded
nearly as strongly as 1-Ga, but that 2-Ga and 3-Ga bind much
more weakly (due to the lack of hydrophobic groups).
Table 1 Docking results of the best poses of 1–5-Ga, PPIX, and ATP to Hsp90. Here snapbe and scored ucav are two measure of the bond strength.
Note that negative numbers for the binding energy indicate stronger bonds. The atom labels of the ligands are shown in Fig. S1 of the ESI
Corrole–Hsp90 complex Snapbe (kcal mol1) Scored ucav (kcal mol1) Type of interaction Interaction Bond length (Å)
1-Ga 150.44 131.54 Salt-bridge (Lys112)NZ–O66 2.8
Salt-bridge (Lys112)NZ–O68 2.7
Non-covalent (Asn51)OD1–C57 4.0
Cation–p (Lys58)NZ–C18 4.1
Anion–p (Asp102)OD1–C37 3.2
Non-covalent (Asn106)OD1–Ga1 3.5
4-Ga 149.27 130.31 H-bond (Asn51)HD21–O67 2.1
Salt-bridge (Lys112)NZ–O70 2.7
Non-covalent (Met98)SD–C55 3.2
5-Ga 107.93 89.39 Salt-bridge (Lys58)NZ–O67 2.7
Cation–p (Lys58)NZ–C21 5.0
Anion–p (Asp102)OD1–C37 3.6
Non-covalent (Asn106)OD1–Ga1 3.1
3-Ga 43.20 33.53 H-bonding (Asn51)HD21–O78 1.8
Anion–p (Asp102)OD2–C56 2.9
2-Ga 31.93 31.66 Anion–p (Asp102)OD1–C60 3.1
PPIX 141.55 118.94 Cation–p (Lys58)NZ–C29 3.4
Salt-bridge (Lys112)NZ–O27 2.7
ATP 288.59 261.30 Salt-bridge (Lys112)NZ–O18 2.6
H-bond (Asn106)HD22–O14 1.9
Salt-bridge (Lys58)NZ–O16 2.5
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Also observed are axial interactions (Fig. 3a and e) as
expected between the Lewis acidic Ga(III) and the amide group
of Asn106.
DFT calculations were also performed to validate the FF
calculations of these interactions (Fig. S2a and b, ESI†).
Comparing the predicted binding energies among 1- to 5-Ga,
PPIX and ATP provides insight into designing of new Hsp90
inhibitors. We find that it is essential for the ligand to have
three hydrophilic groups to achieve maximal binding at the
N-terminal site, which is the ATP binding site and relatively
polar.40 For comparison we docked ATP to the N-terminal
binding pocket, leading to interactions (Fig. 3g) consistent with
those in the X-ray structure (PDB code: 1AM1). Since ATP is much
smaller than the corroles and has more hydrophilic groups,
we find that it binds more strongly than the other ligands
investigated here.
Despite our prediction that ATP binds more strongly to
Hsp90 than PPIX and 1- to 5-Ga, experiments show that PPIX
and hemin directly impede the activation of hypoxia-inducible
factor 1a (HIF-1a) by inhibiting Hsp90.29,48 The molecular
details of the interactions between PPIX and Hsp90 have been
addressed previously by computational docking studies.29 It was
predicted that the conjugated aromatic system of porphyrin ring
could make cation–p interactions with Lys58, while one of the
propionates form a hydrogen bond with Lys112. Indeed, our
docking predictions confirm the purported cation–p interaction
of Lys58 with the porphyrin, and the direct salt-bridge inter-
action of Lys112 with one of the carboxylate groups (Fig. 3f). We
also predict that the Hsp90 binding energy of 1-Ga and 4-Ga is
stronger than that of PPIX, suggesting that 1-Ga and 4-Ga might
be better Hsp90 inhibitors than PPIX.
To confirm our docking results, we carried out 10 ns of MD
simulation on the docked complex 1-Ga–Hsp90. We consider
that 10 ns is sufficient for our analyses because the RMSD
changes of the Hsp90 backbone change are little during the last
5 ns (Fig. S3, ESI†). The key interactions of 1-Ga with Hsp90
(Table 1) were analysed over the 10 ns as shown in Fig. 4. We
find that these important interactions are relatively stable
during the MD simulation (Fig. 5), with expected changes as
water diffuses into the binding site. At the beginning of the
MD simulation, Lys112 seems to be drawn slightly towards
proximal groups (Gly135 and Asn106) probably because of the
Fig. 3 Predicted ligand–Hsp90 structures at the N-terminal binding pocket of Hsp90 – (a) 1-Ga, (b) 2-Ga, (c) 3-Ga, (d) 4-Ga, (e) 5-Ga, (f) PPIX, and
(g) ATP. Dotted lines represent possible interactions and binding modes, and atoms are classified by color according to type. The final pdb files for the
coordinates of 1-Ga–Hsp90 and 4-Ga–Hsp90 are listed in the ESI.†
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initial interactions with the water. However, after 5 ns, the salt-
bridge interaction between the sulfonate group of 1-Ga and the
protonated nitrogen of Lys112 eventually dominates and is
maintained throughout (Fig. 4a). The non-covalent (Asn51
and –C6F5 ring) and cation–p interaction (Lys58 and corrole)
are maintained throughout, while it is noted that the anion–p
interaction between OD1 of Asp102 and the –C6F5 ring is
present but weak. The axial interaction between the gallium
center and the amide group of Asn106 is maintained through-
out with only some aberrations at 9 ns (Fig. 4e). In addition, a
sulfur–p interaction (–S and –C6F5) is observed (Fig. 4c). The
pharmacophore of 1-Ga with Hsp90 is shown in Fig. 6.
From the above analysis, we hypothesized that a ligand that
could form two salt bridges between the corrole and Hsp90
(Lys58 and Lys112) might lead to stronger bonding than 1-Ga.
Since the two sulfonate groups in 1-Ga are not far apart enough
to form salt bridges with both Lys58 and Lys112 simultaneously,
Fig. 4 10 ns MD results of the interaction distances of 1-Ga to Hsp90 starting from the docking pose c4644. (a) Lys112 NZ to O65, O68, (b) Lys58 NZ to
C16, (c) Met98 SD to C50, (d) Asn51 OD1 to C57, (e) Asn106 OD1 to GA1, and (f) Asp102 OD1 to C40.
Fig. 5 Final frame of the MD for 1-Ga/Hsp90 after 10 ns MD. The starting
pose is shown in Fig. S3 (ESI†). Residues important to binding are high-
lighted (color code: red = O, blue = N, white = H, yellow = S, pink = Ga).
Fig. 6 Pharmacophore of 1-Ga to Hsp90. The Ga center interacts with
Asn106 (not shown).
Fig. 7 Structures of 6-Ga and 7-Ga.
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we proposed 6-Ga and 7-Ga (Fig. 7) and carried out both
docking and 10 ns of MD simulations to test their binding
ability to Hsp90. The MD results for 6-Ga are listed in Fig. S5–S8
(ESI†). The binding mode stabilizes after 7 ns (Fig. S5, ESI†),
while the familiar salt-bridge and cation–p interactions are
present (Fig. S8a, b and e, ESI†). The anion–p (Fig. S8c, ESI†)
and sulfur–p (Fig. S8d, ESI†) bond distances are approximately
3.0 Å and 3.5 Å, respectively at the end of 10 ns. However,
we mainly focus on 7-Ga here because 6-Ga is synthetically
unfeasible (it is isolated at 4% yield).49
We predict two interactions (salt-bridge and cation–p)
between Lys58 and Lys 112 with 7-Ga (Fig. 8). The predicted
binding energy (scored ucav energy) for 7-Ga is comparable to
that of 4-Ga and 1-Ga (Table 2).
The results for the 10 ns of MD simulations are summarized
in Fig. 9. We find that the docked binding mode is stable
(Fig. S9, ESI†), with all key interactions from the docking
maintained during the MD (Fig. S10, ESI† and Fig. 10). Moreover
we find the sulfur–p interaction as observed in 1-Ga (Fig. 9b),
Fig. 8 Docking of 7-Ga to the N-terminal binding pocket of Hsp90. The
final pdb files for the coordinates of 7-Ga–Hsp90 are listed in the ESI.†
Table 2 Docking results of 7-Ga to Hsp90
Ligand–Hsp90 complex Snapbe (kcal mol1) Scored ucav (kcal mol1) Type of interaction Interaction Bond length (Å)
7-Ga 145.08 124.50 Salt-bridge (Lys112)NZ–O58 2.9
Cation–p (Lys58)NZ–C28 4.0
Anion–p (Asp102)OD2–C59 4.9
Fig. 9 10 ns MD results of the interaction distances of 7-Ga to Hsp90 starting from the docking pose c23708. (a) Lys112 NZ to O54, Lys112 NZ to O56,
(b) Met98 SD to C43, (c) Lys58 NZ to C11, (d) Asp102 OD1 to C34.
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although both the sulfur–p and anion–p bond distances are
about 1 Å longer than that observed in 6-Ga (Fig. S8, ESI†).
Conclusions
Our docking and MD simulation results suggest that the
experimentally observed cytotoxicity of 1-Ga might be the result
of its inhibition of Hsp90. We also propose a new gallium
corrole derivative, 7-Ga, as a potential Hsp90 inhibitor, suggesting it
as a promising candidate for further experimental investigation.
These studies suggest a new understanding of the tumor-killing
mechanism of metallocorroles, and we have provided a pharmaco-
phore that can help develop this new class of Hsp90 inhibitors.
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